SCHEMBL701927

SCHEMBL701927

O=C1Nc2ccc(Cl)cc2/C1=C/c1ccc(B(O)O)o1

nearest known ligand 0.59

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
RPS6KA3 P51812 1/20 0.59
LRRK2 Q5S007 7/20 0.55
PSEN1 P49768 2/20 0.55
PSEN2 P49810 2/20 0.55
APH1B Q8WW43 2/20 0.55
NCSTN Q92542 2/20 0.55
APH1A Q96BI3 2/20 0.55
PSENEN Q9NZ42 2/20 0.55
PTPN1 P18031 4/20 0.54
PTPN2 P17706 1/20 0.54
PDGFRB P09619 2/20 0.51
IDO1 P14902 1/20 0.51
TDO2 P48775 1/20 0.51
TGM2 P21980 1/20 0.51
RET P07949 2/20 0.49
EGFR P00533 1/20 0.49
ERBB2 P04626 1/20 0.49
PIM1 P11309 1/20 0.48
PIM2 Q9P1W9 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10091750 1.00 RPS6KA3 (0.59) RPS6KA3LRRK2PSEN1PSEN2APH1B
SCHEMBL701928 1.00 RPS6KA3 (0.59) RPS6KA3LRRK2PSEN1PSEN2APH1B
SCHEMBL702178 0.81 RET (0.73) RPS6KA3LRRK2PSEN1PSEN2APH1B
SCHEMBL702179 0.81 RET (0.73) RPS6KA3LRRK2PSEN1PSEN2APH1B
SCHEMBL10091727 0.74 MEN1 (0.60) RPS6KA3LRRK2PSEN1PSEN2APH1B
SCHEMBL10091726 0.74 PIM1 (0.56) RPS6KA3LRRK2PSEN1PSEN2APH1B
SCHEMBL5477805 0.73 LRRK2 (0.83) RPS6KA3LRRK2PSEN1PSEN2APH1B
SCHEMBL5477806 0.73 LRRK2 (0.83) RPS6KA3LRRK2PSEN1PSEN2APH1B
SCHEMBL703105 0.73 PIM1 (0.61) RPS6KA3LRRK2PSEN1PSEN2APH1B
SCHEMBL703106 0.73 PIM1 (0.61) RPS6KA3LRRK2PSEN1PSEN2APH1B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120190669-A1 OXINDOLE COMPOUNDS CYLENE PHARMACEUTICALS, INC. (US) 2012-07-26 US disclosed
US-8124649-B2 Oxindole compounds CYLENE PHARMACEUTICALS, INC. (US) 2012-02-28 US disclosed
EP-2307421-A1 OXINDOLE COMPOUNDS Cylene Pharmaceuticals, Inc. (US) 2011-04-13 EP disclosed
US-20100041635-A1 OXINDOLE COMPOUNDS CYLENE PHARMACEUTICALS, INC. 2010-02-18 US disclosed
WO-2010002933-A1 OXINDOLE COMPOUNDS CYLENE PHARMACEUTICALS, INC. (US) 2010-01-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100041635-A1 OXINDOLE COMPOUNDS FLT3, PIM1, PIM2 RPS6KA3 290/4885LRRK2 604/4885PSEN1 1780/4885
US-20120190669-A1 OXINDOLE COMPOUNDS FLT3, PIM1, PIM2 RPS6KA3 290/4885LRRK2 604/4885PSEN1 1780/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.